# Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

> **NCT04423367** · PHASE2 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 18 (actual)

## Conditions studied

- Acquired Pure Red Cell Aplasia

## Interventions

- **DRUG:** bortezomib/dexamethasone

## Key facts

- **NCT ID:** NCT04423367
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-13
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-09-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423367, "Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04423367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*